双極性障害治療薬の世界市場2017-2021...市場調査レポートについてご紹介

【英文タイトル】Global Bipolar Disorder Therapeutic Market 2017-2021

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Key market highlights

PART 05: Disease overview

PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation by drug class
• Market overview
• Antipsychotics
• Anticonvulsants
• Traditional mood stabilizers
• Others

PART 09: Geographical segmentation
• Bipolar disorder therapeutics market in Americas
• Bipolar disorder therapeutic market in EMEA
• Bipolar disorder therapeutic market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges
• Market drivers
• Impact of drivers on key customer segments
• Market challenges
• Impact of challenges on key customer segments

PART 12: Market trends
• Awareness about bipolar disorder in children (pediatric extension)
• Rising application of combination therapies

PART 13: Vendor landscape
• Competitive scenario

PART 14: Key vendor analysis
• Eli Lilly
• Bristol-Myers Squibb
• AstraZeneca
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

[List of Exhibits]

Exhibit 01: Different types of bipolar disorder
Exhibit 02: Factors causing bipolar disorder
Exhibit 03: Medication guidelines for managing bipolar disorder
Exhibit 04: Global bipolar disorder therapeutics market: Snapshot
Exhibit 05: Global bipolar disorder therapeutic market 2016-2021($ millions)
Exhibit 06: Global bipolar disorder therapeutic market: Opportunity analysis
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline snapshot
Exhibit 09: Pipeline landscape
Exhibit 10: Global bipolar disorder therapeutic market by drug class 2016 and 2021
Exhibit 11: Global bipolar disorder therapeutic market by drug class
Exhibit 12: Uses and side-effects of antipsychotics
Exhibit 13: Global bipolar disorder antipsychotics drugs market 2016-2022 ($ millions)
Exhibit 14: Old generation anticonvulsants for bipolar disorder treatment: Snapshot
Exhibit 15: New generation anticonvulsants for bipolar disorder treatment: Snapshot
Exhibit 16: Uses and side-effects of anticonvulsants
Exhibit 17: Global bipolar disorder antipsychotic drug market 2016-2022 ($ millions)
Exhibit 18: Global bipolar disorder traditional mood stabilizers drug market 2016-2022 ($ millions)
Exhibit 19: Global bipolar disorder therapeutic market for other drugs 2016-2022 ($ millions)
Exhibit 20: Global bipolar disorder therapeutic market by geography 2016 and 2021
Exhibit 21: Bipolar disorder therapeutic market by geography 2016-2021 ($ millions)
Exhibit 22: Market scenario in Americas
Exhibit 23: Bipolar disorder therapeutic market in Americas 2016-2021 ($ millions)
Exhibit 24: Market scenario in EMEA
Exhibit 25: Bipolar disorder therapeutic market in EMEA 2016-2021 ($ millions)
Exhibit 26: Market scenario in APAC
Exhibit 27: Bipolar disorder treatment market in APAC 2016-2021 ($ millions)
Exhibit 28: Economic burden of mental illnesses
Exhibit 29: Initiatives for people with mental disorders
Exhibit 30: Impact of drivers
Exhibit 31: Financial loss due to patent issues
Exhibit 32: Major side-effects of bipolar disorder medications
Exhibit 33: Impact of challenges
Exhibit 34: Competitive structure analysis of global bipolar disorder therapeutic market 2016
Exhibit 35: Strategic success factors of companies in global bipolar disorder therapeutic market
Exhibit 36: Eli Lilly: Key highlights
Exhibit 37: Eli Lilly: Strength assessment
Exhibit 38: Eli Lilly: Strategy assessment
Exhibit 39: Eli Lilly: Opportunity assessment
Exhibit 40: Eli Lilly: YoY growth rate of Zyprexa 2014-2015 ($ millions)
Exhibit 41: Bristol-Myers Squibb: Key highlights
Exhibit 42: Bristol-Myers Squibb: Strength assessment
Exhibit 43: Bristol-Myers Squibb: Strategy assessment
Exhibit 44: Bristol-Myers Squibb: Opportunity assessment
Exhibit 45: Bristol-Myers Squibb: Revenue and YoY growth rate of Abilify 2013-2015 ($ millions)
Exhibit 46: AstraZeneca: Key highlights
Exhibit 47: AstraZeneca: Strength assessment
Exhibit 48: AstraZeneca: Strategy assessment
Exhibit 49: AstraZeneca: Opportunity assessment
Exhibit 50: AstraZeneca: Revenue and YoY growth rate of Seroquel 2013-2015 ($ millions)


【レポート販売概要】

■ タイトル:双極性障害治療薬の世界市場2017-2021
■ 英文:Global Bipolar Disorder Therapeutic Market 2017-2021
■ 発行日:2017年4月12日
■ 調査会社:Technavio
■ 商品コード:IRTNTR12440
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。